• Profile
Close

FDA approves single-use prefilled aflibercept syringe

American Academy of Ophthalmology News Aug 16, 2019

Aflibercept (Eylea) will soon be available in a 2-mg sterile prefilled syringe, according to a press release by Regeneron Pharmaceuticals. Prior to the FDA’s approval—which comes almost 3 years after the agency first cleared prefilled ranibizumab syringes—aflibercept had only been available in single-dose vials.

"This approval may help doctors more conveniently and efficiently deliver Eylea to appropriate patients," said George D. Yancopoulos, MD, PhD, Regeneron’s president and chief scientific officer.

Aflibercept is indicated to treat 4 retinal diseases—wet AMD, macular edema secondary to retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Regeneron expects the prefilled syringes to be available later this year.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay